Research
Hormonal
Ghrelin functions as a meal-initiation signal in humans, with preprandial increases correlating with hunger, and its levels are suppressed by food intake, although its role in long-term weight regulation is less clear than leptin's.
Ghrelin is your body's 'start eating' signal. It rises before meals and drops after. In obesity, ghrelin levels are actually lower than in lean people, but the system may be oversensitive. Understanding that hunger is a hormonal signal helps normalize the experience of hunger as a biological event, not a failure of will.
GoodSupportsHIGH confidence
Ghrelin seems to function as a meal-initiation signal in the system for short-term regulation of energy balance... Ghrelin levels show preprandial increases and postprandial decreases... Ghrelin attenuates leptin-induced reduction in food intake and body weight by modulating the expression of various hypothalamic peptides.
Why this rating
Supported by multiple human and animal studies cited.
Source
The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review
Melanie D. Klok et al. · Obesity Reviews · 2006
DOI 10.1111/j.1467-789x.2006.00270.x
narrative_reviewCited 1,434×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In obese humans, circulating leptin levels are elevated while ghrelin levels are decreased, and the body exhibits leptin resistance, meaning high leptin fails to suppress food intake or increase energy expenditure as it does in lean individuals.Good
- Leptin resistance in obesity is likely caused by defective transport of leptin across the blood-brain barrier (BBB) and/or downregulation of hypothalamic leptin receptors, rather than a lack of leptin production.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →